Haemonetics (HAE), a healthcare company, said that, based on preliminary information, it expects to report revenue of $220 million and adjusted earnings approximating $0.40 per diluted share for its second fiscal 2016 quarter ended September 26, 2015.
Ten analysts, on average, were predicting revenue of $226.5 million and earnings of $0.39 per diluted share.
The company has also revised its previously-issued revenue and adjusted earnings guidance for the full fiscal year 2016.
Revenue is now expected to be within the range of $910-$920 million, representing 0-1% growth, which is below previous guidance of 4-6% growth. Analysts were looking for $946.8 million, or 4% growth.
Fiscal year 2016 adjusted earnings guidance is revised to a range of $1.65 – $1.75 per share, which is below the previous guidance range of $1.98 – $2.08 per share. Analysts on average had predicted earnings of $2.02 per diluted share.
Shares of the Braintree, Massachusetts-based company closed down 2.2% at $33.38 on Monday, stretching this year’s slump to 11%